Welcome to our dedicated page for Monopar Therapeutics SEC filings (Ticker: MNPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Monopar Therapeutics Inc. (MNPR) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Monopar uses current reports on Form 8-K to communicate material information about its operations, clinical programs, financial results, and corporate actions.
For this clinical-stage biopharmaceutical company, filings related to drug development are particularly important. Recent 8-K reports reference press releases on ALXN1840 (tiomolybdate choline) for Wilson disease, including copper balance data, long-term neurological efficacy and safety analyses, and presentations at major scientific meetings. Other filings describe progress in the company’s MNPR-101-based radiopharmaceutical programs, such as U.S. Food and Drug Administration clearance of an investigational new drug (IND) application for MNPR-101-Lu in uPAR-expressing advanced or metastatic solid tumors.
Monopar’s SEC filings also cover financial and capital markets information, including quarterly financial results, underwritten offerings of common stock and pre-funded warrants conducted under a shelf registration statement on Form S-3, and related share repurchase agreements with significant stockholders. Additional filings detail outcomes of the annual meeting of stockholders, such as the election of directors, advisory votes on executive compensation, and ratification of the independent registered public accounting firm.
On this page, users can review Monopar’s Forms 8-K and other available filings, and use AI-powered summaries to understand the key points in complex documents. These tools can help highlight disclosures related to ALXN1840, MNPR-101-Zr, MNPR-101-Lu, MNPR-101-Ac, capital raises, index inclusion, and governance matters, without needing to read every page of the underlying SEC reports.
Monopar Therapeutics Inc. (MNPR) filed an 8-K to disclose the results of its 17 June 2025 Annual Meeting of Stockholders. Of the 6,115,214 shares entitled to vote, 82.6% (5,048,394) were represented in person or by proxy.
- Director elections: All six nominees—including CEO Chandler D. Robinson and Chair Christopher M. Starr—were elected. Support ranged from 78.7% to 99.9% of votes cast, with 655,826 broker non-votes recorded for each nominee.
- Say-on-pay: Executive compensation was approved with 4,382,795 votes for (99.8%), 2,933 against, and 6,840 abstentions.
- Say-on-pay frequency: Shareholders selected an annual advisory vote, receiving 4,383,765 votes, dwarfing biennial (1,247) and triennial (1,212) options.
- Auditor ratification: BPM LLP was ratified as independent accountant for FY-2025 with 5,044,817 votes for (99.9%).
No other matters were submitted. The outcome signals continued shareholder support for current governance, compensation practices, and audit oversight. No immediate financial impact or strategic change was disclosed.